TY - JOUR
T1 - Supraciliary micro-stent implantation for open-angle glaucoma failing topical therapy
T2 - 1-year results of a multicenter study
AU - García-Feijoo, Julian
AU - Rau, Magda
AU - Grisanti, Swaantje
AU - Grisanti, Salvatore
AU - Höh, Helmut
AU - Erb, Carl
AU - Guguchkova, Pravoslava
AU - Ahmed, Iqbal
AU - Grabner, Günther
AU - Reitsamer, Herbert
AU - Shaarawy, Tarek
AU - Ianchulev, Tsontcho
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Purpose To evaluate the safety and efficacy of a supraciliary micro-stent (CyPass Micro-Stent; Transcend Medical, Menlo Park, California, USA) for surgical treatment of glaucoma in patients refractory to topical medications. Design Multicenter, single-arm interventional study. Methods Patients with open-angle glaucoma (Shaffer Grade 3 and 4) and uncontrolled medicated intraocular pressure (IOP) >21 mm Hg at baseline and candidates for conventional glaucoma surgery were enrolled. Glaucoma medications were discontinued at surgery and resumed at investigator discretion. CyPass Micro-Stent implantation was completed in all patients using a standard clear corneal approach. Adverse events, postoperative IOP changes, and need for IOP-lowering medications during the first 12 postoperative months (12M) were monitored. Results Sixty-five eyes were enrolled, and 55 were available at 12M, accounting for loss to follow-up and early termination. Baseline IOP was 24.5 ± 2.8 mm Hg, and the mean number of medications recorded was 2.2 ± 1.1. There were no serious intraoperative events or major adverse events (eg, retinal or choroidal detachment, persistent uveitis, persistent hyphema, hypotony maculopathy). The most common adverse events included IOP increases >30 mm Hg beyond 1 month (11%, 7/65), transient hyphema (6%, 4/65), and cataract progression (12%, 5/41 phakic eyes). Mean IOP was 16.4 ± 5.5 mm Hg at 12 months - a 34.7% reduction (P <.0001). Mean medication usage also decreased from baseline to a mean of 1.4 ± 1.3 medications at 12M (P =.002). In eyes originally indicated for conventional glaucoma surgery, no secondary surgery was performed in 83% (53/64). Conclusion Supraciliary stenting with the CyPass Micro-Stent effectively lowers IOP as a surgical treatment for glaucoma, precluding the need for more invasive glaucoma surgery in >80% of patients at 1 year, thereby reducing postoperative glaucoma surgical complications.
AB - Purpose To evaluate the safety and efficacy of a supraciliary micro-stent (CyPass Micro-Stent; Transcend Medical, Menlo Park, California, USA) for surgical treatment of glaucoma in patients refractory to topical medications. Design Multicenter, single-arm interventional study. Methods Patients with open-angle glaucoma (Shaffer Grade 3 and 4) and uncontrolled medicated intraocular pressure (IOP) >21 mm Hg at baseline and candidates for conventional glaucoma surgery were enrolled. Glaucoma medications were discontinued at surgery and resumed at investigator discretion. CyPass Micro-Stent implantation was completed in all patients using a standard clear corneal approach. Adverse events, postoperative IOP changes, and need for IOP-lowering medications during the first 12 postoperative months (12M) were monitored. Results Sixty-five eyes were enrolled, and 55 were available at 12M, accounting for loss to follow-up and early termination. Baseline IOP was 24.5 ± 2.8 mm Hg, and the mean number of medications recorded was 2.2 ± 1.1. There were no serious intraoperative events or major adverse events (eg, retinal or choroidal detachment, persistent uveitis, persistent hyphema, hypotony maculopathy). The most common adverse events included IOP increases >30 mm Hg beyond 1 month (11%, 7/65), transient hyphema (6%, 4/65), and cataract progression (12%, 5/41 phakic eyes). Mean IOP was 16.4 ± 5.5 mm Hg at 12 months - a 34.7% reduction (P <.0001). Mean medication usage also decreased from baseline to a mean of 1.4 ± 1.3 medications at 12M (P =.002). In eyes originally indicated for conventional glaucoma surgery, no secondary surgery was performed in 83% (53/64). Conclusion Supraciliary stenting with the CyPass Micro-Stent effectively lowers IOP as a surgical treatment for glaucoma, precluding the need for more invasive glaucoma surgery in >80% of patients at 1 year, thereby reducing postoperative glaucoma surgical complications.
UR - http://www.scopus.com/inward/record.url?scp=84929131899&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.02.018
DO - 10.1016/j.ajo.2015.02.018
M3 - Article
C2 - 25747677
AN - SCOPUS:84929131899
SN - 0002-9394
VL - 159
SP - 1075-1081.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 6
ER -